Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 3032950 in moderate to severe ulcerative colitis
2023-509544-10-00Phase 2Authorised
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of BI 3032950 in autoimmune colitis, sponsored by Boehringer Ingelheim. Primary endpoint: Clinical remission at Week 12. Planned start Jan 2025; status: authorised.
02
Drugs
BI 3032950
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2023-509544-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509544-10-00.